Compare Hilton Hotels Corporation Common Stock (HLT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Mesoblast Limited — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.94 (market cap $73.63B), while Mesoblast Limited trades at $16.38 (market cap $2.17B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 33.9× Mesoblast Limited's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| HLT | MESO | |
|---|---|---|
Market Cap | $73.63B | $2.17B |
Sector | Consumer Cyclical | Technology |
52-Week High | $350.22 | $20.96 |
52-Week Low | $256.75 | $12.88 |
Enterprise Value | $86.12B | $2.17B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $323.94, up 0.82% with a bearish technical signal despite recent earnings beats. Revenue grew to $12.04B in 2025 with a net income margin of 12.56%, though the P/E ratio of 49.38 suggests premium valuation. The stock faces headwinds from negative equity and rising debt-to-asset ratio, now at 73.88% for 2025. Analyst consensus remains bullish with a $343.40 price target, and recent news highlights earnings optimism ahead of Q2 2026 results.
Outlook: Strong travel demand and consistent earnings beats support growth, but high leverage and valuation pose risks. Opportunities include brand expansion and operational efficiency, while risks involve debt servicing and economic sensitivity. Investors should weigh analyst optimism against fundamental pressures.
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
